<?xml version='1.0' encoding='utf-8'?>
<document id="22610723"><sentence text="Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder."><entity charOffset="0-10" id="DDI-PubMed.22610723.s1.e0" text="Guanfacine" /></sentence><sentence text="Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder associated with a wide range of impairments" /><sentence text=" Psychostimulants are generally first-line pharmacotherapy, but symptom improvement is suboptimal in some patients" /><sentence text=" In these patients, clinicians frequently use a combination of psychostimulants and nonscheduled medications to manage ADHD, although published evidence supporting this practice was relatively scarce until recently" /><sentence text="Guanfacine extended release (GXR), a selective alpha2A-adrenoceptor agonist, is approved as a monotherapy and adjunctive therapy to psychostimulant medications for ADHD in patients 6-17 years of age"><entity charOffset="0-10" id="DDI-PubMed.22610723.s5.e0" text="Guanfacine" /></sentence><sentence text=" Drug-drug interaction studies have demonstrated that the adjunctive administration of GXR with a long-acting methylphenidate preparation or lisdexamfetamine dimesylate did not change exposure to the active components of either medication in a clinically meaningful way compared with either treatment alone"><entity charOffset="110-125" id="DDI-PubMed.22610723.s6.e0" text="methylphenidate" /><entity charOffset="141-168" id="DDI-PubMed.22610723.s6.e1" text="lisdexamfetamine dimesylate" /><pair ddi="false" e1="DDI-PubMed.22610723.s6.e0" e2="DDI-PubMed.22610723.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22610723.s6.e0" e2="DDI-PubMed.22610723.s6.e1" /></sentence><sentence text="Data supporting the potential efficacy of GXR adjunctive to psychostimulants were preliminarily observed in a 9-week, open-label, dose-escalation study and subsequent extension study (â‰¤ 24 months) in subjects aged 6-17 years with suboptimal control of ADHD symptoms on psychostimulant monotherapy" /><sentence text=" In a subsequent 9-week, randomized, double-blind, placebocontrolled study of subjects aged 6-17 years with suboptimal response to a long-acting, extendedrelease, oral psychostimulant, adjunctive GXR (administered in the morning or evening) was associated with significantly greater symptom reduction than placebo and psychostimulant (ADHD Rating Scale IV [ADHD-RS-IV] total score, placebo-adjusted least squares mean reductions: GXR AM, -4" /><sentence text="5, P = 0" /><sentence text="002; GXR PM, -5" /><sentence text="3, P &lt; 0" /><sentence text="001, based on Dunnett's test)" /><sentence text=" Across multiple studies, the safety and tolerability profile of GXR administered adjunctively to psychostimulants has been consistent with the known profiles of each medication" /><sentence text=" Additional studies should further explore the role of adjunctive GXR in clinical practice to help identify those patients most likely to benefit from such therapy" /><sentence text="" /></document>